MarketCapExport financials
IRadimed Corporation (IRMD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
IRadimed Corporation Income Statement 2025-2011 | IRMD
Brief overview of financial performance at IRadimed Corporation
The overview follows changes across a five-year period. The revenue attributed to IRadimed Corporation moved from $31.7 million to $83.8 million between the two endpoints. The cumulative result was +164.3%, corresponding to roughly 21.5% per year. The annual growth rate indicates an exceptionally strong top-line trend.
Gross profit changed from $23.6 million to $64.3 million (+172.9%). The cost base moved more slowly than the top line, which supported margins. Comparing the endpoints gives gross margins of 74.3% and 76.7%. The margin shift points to a more favorable sales-and-cost structure.
Over the period, EBITDA shifted from $583 thousand to $27.3 million, a change of +4587.1%. EBITDA expanded faster than the top line. EBITDA margin moved from 1.8% to 32.6%. A wider margin confirms stronger operating efficiency.
The net result moved from $1.4 million to $22.5 million, or +1542.1%. Net profit ended the five years at a local peak.
Over the period, capitalization shifted from $304 million to $1.3 billion (+312.6%). The financial trend was stronger than the market valuation.
Financial takeaway
The results point to consistent and sustainable progress. The strongest signals are sales growth, improving net profitability and improving gross profitability. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement IRadimed Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.25 B | 670 M | 525 M | 490 M | 571 M | 304 M | 292 M | 287 M | 154 M | 96.8 M | 214 M | 128 M | - | - | - |
Shares |
12.7 M | 12.7 M | 12.6 M | 12.6 M | 12.3 M | 12.3 M | 11.3 M | 10.8 M | 10.6 M | 10.8 M | 11 M | 8.74 M | - | - | - |
Historical Prices |
98.5 | 52.9 | 41.6 | 39 | 46.2 | 22.8 | 23.4 | 24.5 | 15.2 | 11.1 | 28 | 12.9 | - | - | - |
Net Income |
22.5 M | 19.2 M | 17.2 M | 12.8 M | 9.33 M | 1.37 M | 9.63 M | 6.3 M | 500 K | 7.21 M | 7.53 M | 2.05 M | 1.94 M | 966 K | - |
Revenue |
83.8 M | 73.2 M | 65.6 M | 53.3 M | 41.8 M | 31.7 M | 38.5 M | 30.4 M | 23.1 M | 32.5 M | 31.6 M | 15.7 M | 11.3 M | 7.69 M | - |
Cost of Revenue |
19.5 M | 16.9 M | 15.4 M | 12 M | 9.76 M | 8.14 M | 8.82 M | 7.21 M | 5.57 M | 6.15 M | 5.84 M | 3.4 M | 2.85 M | - | - |
Gross Profit |
64.3 M | 56.4 M | 50.2 M | 41.3 M | 32 M | 23.6 M | 29.7 M | 23.2 M | 17.5 M | 26.3 M | 25.8 M | 12.2 M | 8.49 M | 5.56 M | - |
Operating Income |
26.1 M | 22 M | 20 M | 15.6 M | 9.82 M | -756 K | 8.65 M | 6 M | 1.29 M | 10.9 M | 11.5 M | 3.07 M | 2.79 M | - | - |
Interest Expense |
- | 164 K | - | - | - | - | - | - | - | -2.05 K | -3.52 K | 2.72 K | - | - | - |
EBITDA |
27.3 M | 22.8 M | 20.8 M | 16.3 M | 11.2 M | 583 K | 9.89 M | 7.11 M | 2.59 M | 11.2 M | 11.7 M | 3.21 M | 2.93 M | 1.53 M | - |
Operating Expenses |
38.2 M | 34.4 M | 30.1 M | 25.7 M | 22.2 M | 24.3 M | 21.1 M | 17.2 M | 16.2 M | 15.4 M | 14.2 M | 9.18 M | 5.7 M | 4.13 M | - |
General and Administrative Expenses |
17.8 M | 15.9 M | 15.1 M | 10.7 M | 9.77 M | 12.3 M | 10.5 M | 8.71 M | 9 M | 8.8 M | 7.77 M | 4.82 M | 2.39 M | 1.55 M | - |
All numbers in USD currency
Quarterly Income Statement IRadimed Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
12.8 M | 12.8 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 12.5 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 12.2 M | 12.1 M | 11.9 M | 11.8 M | 11.4 M | 11.2 M | 11 M | 11 M | 10.8 M | 10.7 M | 10.6 M | 10.6 M | 10.6 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 10.8 M | 11.1 M | 11.2 M | 11 M | 11 M | 10.9 M | 10.8 M | 10.1 M | 7 M | 7 M | 7 M | 7 M | 7 M | - | - | - | - | - | - | - | - | - |
Net Income |
5.22 M | 5.82 M | 5.58 M | 5.77 M | 4.69 M | - | 5.05 M | 4.9 M | 4.14 M | - | 5.07 M | 4.18 M | 3.41 M | - | 3.43 M | 3.24 M | 2.49 M | - | 2.58 M | 1.47 M | 1.39 M | - | 1.07 M | -2.11 M | 1.77 M | - | 2.45 M | 2.09 M | 1.85 M | - | 2.4 M | 1.35 M | 841 K | - | 192 K | 357 K | -233 K | - | 1.56 M | 2.23 M | 2.28 M | - | 1.87 M | 1.77 M | 1.49 M | - | 237 K | 1.02 M | 523 K | - | 261 K | 558 K | - | - | - | - | - | - | - | - | - |
Revenue |
20.5 M | 22 M | 21.2 M | 20.4 M | 19.5 M | - | 18.3 M | 17.9 M | 17.6 M | - | 16.5 M | 16.1 M | 15.5 M | - | 13.4 M | 12.7 M | 12.3 M | - | 10.9 M | 9.81 M | 9.22 M | - | 7.7 M | 6.79 M | 8.68 M | - | 9.96 M | 9.23 M | 8.44 M | - | 7.61 M | 7.38 M | 7.11 M | - | 5.69 M | 5.52 M | 5.16 M | - | 7.67 M | 9.87 M | 8.96 M | - | 8.19 M | 7.61 M | 6.99 M | - | 3.81 M | 4.7 M | 3.56 M | - | 2.48 M | 2.78 M | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
5.31 M | 5.16 M | 4.71 M | 4.45 M | 4.67 M | - | 4.13 M | 3.92 M | 4.21 M | - | 3.67 M | 3.94 M | 3.75 M | - | 2.86 M | 2.58 M | 2.93 M | - | 2.5 M | 2.48 M | 2.16 M | - | 1.96 M | 1.86 M | 2.21 M | - | 2.17 M | 1.86 M | 2.05 M | - | 1.83 M | 1.71 M | 1.69 M | - | 1.31 M | 1.23 M | 1.39 M | - | 1.41 M | 1.74 M | 1.71 M | - | 1.59 M | 1.42 M | 1.33 M | - | 960 K | 870 K | 656 K | - | 670 K | 768 K | - | - | - | - | - | - | - | - | - |
Gross Profit |
15.2 M | 16.8 M | 16.5 M | 16 M | 14.8 M | - | 14.2 M | 14 M | 13.4 M | - | 12.8 M | 12.2 M | 11.7 M | - | 10.5 M | 10.1 M | 9.38 M | - | 8.41 M | 7.33 M | 7.06 M | - | 5.74 M | 4.93 M | 6.46 M | - | 7.8 M | 7.37 M | 6.39 M | - | 5.79 M | 5.67 M | 5.42 M | - | 4.38 M | 4.29 M | 3.77 M | - | 6.27 M | 8.13 M | 7.26 M | - | 6.6 M | 6.19 M | 5.66 M | - | 2.85 M | 3.83 M | 2.9 M | - | 1.81 M | 2.01 M | - | - | - | - | - | - | - | - | - |
Operating Income |
6.39 M | 7.24 M | 6.83 M | 6.79 M | 5.43 M | - | 5.79 M | 5.63 M | 4.75 M | - | 5.91 M | 4.96 M | 4.01 M | - | 4.13 M | 4.17 M | 3.07 M | - | 3.09 M | 1.84 M | 1.78 M | - | 785 K | -2.93 M | 737 K | - | 2.52 M | 2.38 M | 1.51 M | - | 1.45 M | 1.68 M | 1.09 M | - | 196 K | 328 K | -238 K | - | 2.59 M | 3.34 M | 3.48 M | - | 3.2 M | 2.69 M | 2.26 M | - | 406 K | 1.61 M | 824 K | - | 356 K | 780 K | - | - | - | - | - | - | - | - | - |
EBITDA |
7.26 M | 7.69 M | 7.09 M | 6.92 M | 5.63 M | - | 5.93 M | 5.77 M | 4.97 M | - | 6.07 M | 5.13 M | 4.19 M | - | 4.27 M | 4.31 M | 3.51 M | - | 4.11 M | 1.98 M | 2.11 M | - | 1.78 M | -2.26 M | 1.08 M | - | 3.48 M | 3.05 M | 1.9 M | - | 2.29 M | 2.51 M | 1.52 M | - | 1.17 M | 960 K | 48.7 K | - | 3.3 M | 3.46 M | 3.54 M | - | 3.37 M | 2.8 M | 2.32 M | - | 506 K | 1.66 M | 845 K | - | 454 K | 845 K | - | - | - | - | - | - | - | - | - |
Operating Expenses |
8.77 M | 9.58 M | 9.66 M | 9.17 M | 9.41 M | - | 8.4 M | 8.38 M | 8.64 M | - | 6.93 M | 7.22 M | 7.71 M | - | 6.41 M | 5.97 M | 6.3 M | - | 5.32 M | 5.49 M | 5.29 M | - | 4.96 M | 7.86 M | 5.73 M | - | 5.28 M | 4.99 M | 4.88 M | - | 4.34 M | 3.99 M | 4.33 M | - | 4.19 M | 3.96 M | 4.01 M | - | 3.67 M | 4.79 M | 3.78 M | - | 3.4 M | 3.49 M | 3.4 M | - | 2.45 M | 2.22 M | 2.08 M | - | 1.45 M | 1.23 M | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
3.87 M | 4.57 M | 4.36 M | 4.28 M | 4.61 M | - | 3.97 M | 4.1 M | 3.99 M | - | 3.62 M | 3.31 M | 3.92 M | - | 2.88 M | 2.4 M | 2.72 M | - | 2.25 M | 2.56 M | 2.43 M | - | 2.2 M | 5 M | 2.86 M | - | 2.61 M | 2.46 M | 2.41 M | - | 2.18 M | 2.08 M | 2.3 M | - | 2.55 M | 2.19 M | 2.11 M | - | 1.87 M | 3.09 M | 2.26 M | - | 1.68 M | 1.99 M | 1.97 M | - | 1.26 M | 1.13 M | 1.09 M | - | 641 K | 528 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company IRadimed Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
$ 43.32 | 0.04 % | $ 1.99 B |  USA |
 |
Bruker Corporation
BRKR
|
$ 59.67 | 0.18 % | $ 9.06 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
$ 8.73 | 1.16 % | $ 637 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
$ 14.97 | 13.03 % | $ 424 M | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
CONMED Corporation
CNMD
|
$ 45.8 | 3.31 % | $ 1.42 B | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 4.91 | 0.75 % | $ 306 M | USA |
 |
Delcath Systems
DCTH
|
$ 15.96 | 1.8 % | $ 572 M | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
AdaptHealth Corp.
AHCO
|
$ 5.7 | 0.43 % | $ 770 M | USA |
 |
Electromed
ELMD
|
$ 27.57 | 0.11 % | $ 228 M | USA |
 |
Establishment Labs Holdings
ESTA
|
$ 67.76 | 3.69 % | $ 2.01 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
$ 86.82 | 0.51 % | $ 50.8 B | USA |
 |
Align Technology
ALGN
|
$ 148.17 | 4.36 % | $ 10.7 B | USA |
 |
Helius Medical Technologies
HSDT
|
$ 2.88 | 2.45 % | $ 63.5 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
$ 15.53 | 2.76 % | $ 1.19 B | USA |
 |
Inogen
INGN
|
$ 5.09 | 2.55 % | $ 135 M | USA |
 |
Inspire Medical Systems
INSP
|
$ 69.06 | 0.57 % | $ 2.03 B | USA |
 |
IRIDEX Corporation
IRIX
|
$ 0.63 | 0.08 % | $ 10.7 M | USA |
 |
Integer Holdings Corporation
ITGR
|
$ 126.32 | 0.02 % | $ 4.39 B | USA |
|
LENSAR
LNSR
|
$ 7.15 | 0.14 % | $ 85.5 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Apyx Medical Corporation
APYX
|
$ 2.95 | 1.37 % | $ 121 M | USA |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Medtronic PLC
MDT
|
$ 89.3 | 0.08 % | $ 114 B | USA |
 |
MiMedx Group
MDXG
|
$ 4.77 | 0.2 % | $ 705 M | USA |
 |
Accuray Incorporated
ARAY
|
$ 0.23 | 1.0 % | $ 28.2 M | USA |
 |
Myomo
MYO
|
$ 1.64 | 0.3 % | $ 68.6 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.7 | 0.45 % | $ 45.4 M | Israel |
 |
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M |  Britain |
 |
InspireMD
NSPR
|
$ 0.74 | 0.16 % | $ 47.6 M | Israel |
 |
Orthofix Medical
OFIX
|
$ 9.18 | 2.23 % | $ 364 M |  Curacao |
 |
Outset Medical
OM
|
$ 3.09 | 5.45 % | $ 47 K | USA |
 |
Boston Scientific Corporation
BSX
|
$ 44.62 | 0.31 % | $ 66.1 B | USA |
 |
Insulet Corporation
PODD
|
$ 136.49 | 0.01 % | $ 9.6 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 5.74 | 0.16 % | $ 174 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.16 | 4.93 % | $ 135 M | USA |
 |
AVITA Medical
RCEL
|
$ 10.95 | 0.61 % | $ 305 M |  Australia |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Sintx Technologies
SINT
|
$ 1.78 | 3.98 % | $ 4.94 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 26.82 | 0.07 % | $ 23.3 B | Britain |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |
 |
Sensus Healthcare
SRTS
|
$ 3.03 | 0.32 % | $ 49.5 M | USA |
 |
Stryker Corporation
SYK
|
$ 273.4 | 0.38 % | $ 104 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 22.43 | 0.55 % | $ 513 M | USA |
 |
TELA Bio
TELA
|
$ 1.3 | 0.71 % | $ 61 M | USA |
 |
Viemed Healthcare
VMD
|
$ 8.8 | 1.24 % | $ 342 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.05 % | $ 764 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |